<DOC>
	<DOCNO>NCT02508584</DOCNO>
	<brief_summary>M. A. suffers hypogammaglobulinemia complicate refractory Mycoplasma hominis septic arthritis . He receive antibiotic valnemulin Emergency Investigational New Drug ( eIND ) 114686 follow many prior treatment standard antibiotic . M.A . also receive intravenous immunoglobulin ( IVIG ) replacement . The antibiotic IVIG helpful , sufficient cure . Antibodies show critical defense mycoplasma . Hyperimmune serum mycoplasma isolated rabbit goat effective case chronic erosive arthritis set immune deficiency , case result cure . The investigator propose use M. hominis isolate M. A. vaccinate one transgenic cow ( developed SAB Biotherapeutics ) , purify human antibody vaccination , test purify antibody kill assay confirm potency , administer purify human IgG M. A. FDA compassionate use IND application local Institutional Review Board ( IRB ) approval .</brief_summary>
	<brief_title>Personalized Immunotherapeutic Antibiotic-resistant Infection</brief_title>
	<detailed_description>M. A. suffers hypogammaglobulinemia complicate refractory Mycoplasma hominis septic arthritis . He receive antibiotic valnemulin Emergency Investigational New Drug ( eIND ) 114686 follow many prior treatment standard antibiotic . M.A . also receive intravenous immunoglobulin ( IVIG ) replacement . The antibiotic IVIG helpful , sufficient cure . Antibodies show critical defense mycoplasma . Hyperimmune serum mycoplasma isolated rabbit goat effective case chronic erosive arthritis set immune deficiency , case result cure . SAB Biotherapeutics , Inc. ( formerly Sanford Applied Biosciences , LLC ) locate Sioux Falls , SD , develop transchromosomic ( Tc ) cow contain human immunoglobulin ( Ig ) heavy ( IgH ) light ( IgL ) chain loci setting inactivated bovine IgH Ig lambda locus . To date , SAB Biotherapeutics ( SAB ) several product development test animal model , date human trial . Investigators propose use M. hominis isolate M. A. vaccinate one transgenic cow , purify antibody vaccination , test purify antibody kill assay confirm potency , administer purify human IgG M. A. FDA compassionate use IND application local Institutional Review Board ( IRB ) approval . M. A. highly educate person full decision making capacity well aware uncertainty risk associate treatment . This proposal design offer patient alternative perhaps curative approach disease .</detailed_description>
	<mesh_term>Infection</mesh_term>
	<mesh_term>Communicable Diseases</mesh_term>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Agammaglobulinemia</mesh_term>
	<mesh_term>Arthritis , Infectious</mesh_term>
	<mesh_term>Anti-Bacterial Agents</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<criteria>Adult decision make capacity afflict chronic mycoplasma hominis septic arthritis despite standard treatment .</criteria>
	<gender>Male</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>